| Mr Bradley Oliver Levy, LICSW | |
|
1353 Dorchester Ave, Boston, MA 02122-2932 | |
| (617) 288-3230 | |
| (617) 282-0954 |
| Full Name | Mr Bradley Oliver Levy |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 1353 Dorchester Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003098484 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 115769 (Massachusetts) | Primary |
| Entity Name | Thrive Counseling Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215181300 PECOS PAC ID: 0749458420 Enrollment ID: O20110725000191 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.
Research will be reported at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), that demonstrates that early intervention saves lives in women who have a heart attack or unstable chest pain.
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.
The UK's first national investigation into suicide in children and young people is being set up by The University of Manchester to examine causes and recommend prevention strategies.
› Verified 7 days ago
| Entity Name | Grow Healthcare Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245845932 PECOS PAC ID: 3476961368 Enrollment ID: O20221007001608 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.
Research will be reported at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), that demonstrates that early intervention saves lives in women who have a heart attack or unstable chest pain.
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.
The UK's first national investigation into suicide in children and young people is being set up by The University of Manchester to examine causes and recommend prevention strategies.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Bradley Oliver Levy, LICSW 1353 Dorchester Ave, Dorchester, MA 02122-2932 Ph: (617) 288-3230 | Mr Bradley Oliver Levy, LICSW 1353 Dorchester Ave, Boston, MA 02122-2932 Ph: (617) 288-3230 |
News Archive
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.
The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.
Research will be reported at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), that demonstrates that early intervention saves lives in women who have a heart attack or unstable chest pain.
NeurAxon, Inc., a development-stage pharmaceutical company that is designing and developing next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced that it has closed the sale of approximately $8.75 million of unsecured subordinated 2.0% convertible debentures that are convertible under specified circumstances into existing class B preferred shares.
The UK's first national investigation into suicide in children and young people is being set up by The University of Manchester to examine causes and recommend prevention strategies.
› Verified 7 days ago
Julie Ann Hansen, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 857-218-4309 | |
Ms. Bridget Kiely Chiaruttini, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 208 W Springfield St Apt 3, Boston, MA 02118 Phone: 617-852-2830 | |
Mrs. Mary Ray Mazaka, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1153 Centre St, 2nd Floor, Boston, MA 02130 Phone: 617-983-7233 Fax: 617-983-7231 | |
Mr. Timothy Roy, BA, MSW, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 780 American Legion Hwy, Preschool Outreach Program, Boston, MA 02131 Phone: 617-469-8500 | |
Ms. Soyun Kwan, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Children's Hospital Boston, Boston, MA 02115 Phone: 617-355-0567 Fax: 617-730-0208 | |
Sarah Bayer, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 780 Albany St, Boston, MA 02118 Phone: 857-654-1000 |